Reality is that Q is not a marketable product.REMs, bad label, multiple restrictions, cardio risk, birth defects, low profit margin per Rx,.... labs every 30 days, liability for Docs who prescribe, .... No BP interest in Q and the Stendra deal was for peanuts.; Vivus balance sheet is very weak, more dilution coming......Everyone already knows all this....... or so we thought .....
If you believe your own words, you should buy more VVUS, why would you bother spending a second here....hmmmmm????
WS expected $-.08 and there was no 2014 projection, not even a range for Belviq sales .....not even a reference to Eisai's expectation of "dramatically higher sales in 2014"......should have been a little less conservative. But, this is better that overstating and taking a hit later IMO. Maybe Jack will beef up the Belviq story in the conference call.
Stock is reacting nicely to today's news. Arena management needs to work on marketing the company something broader than the leader in weight loss. It will be interesting to see the TV ads to see how they position Belivq. Certainly the main emphasis will be on weight loss, but there is so much that can be said as well ...
Arena Pharmaceuticals(ARNA) was up 2.5% at $6.15 in pre-market Monday after saying it has secured improved patient access of BELVIQ (lorcaserin HCl) with two healthcare benefit companies, and that the estimated number of insured commercial lives in the United States that have coverage for BELVIQ now exceeds 50 percent.
Exactly, they took out $8 and $7.5 and were going for $7. Anyone with half a bfrain could spot the manipulation .....if they wanted to.....IMO, there is just too much corruption ....to expect anyone to do their job..
The global market for obesity products and drugs alone is over $600 Billion. Areana has the only viable drug on the market.
It is best if you do your own research before you invest. We have already done ours....we wouldn't want our educated, fact-based bias to influence you.
Here. Most at $1.31.
Fundamentals are so good that this is now a long term hold. Primary factors: Belviq Safety, Belviq (Weight loss) sales growth, A1C reduction, addictions potential, pipeline, partnerships, no competition, $250M cash, more Belviq approvals coming (regions and indications), .....etc..... buy-out potential, short squeeze potential, minimal downside .....etc..... :)